Pancreatic Cancer Research

ResearcherBeth Israel Deaconess Medical CenterActive in the last 2 years

Charles M. Vollmer

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110148781, A5130094828. Sources: OpenAlex.

Their work

Papers
21 (first author 6, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
126
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 4 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 21

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  3. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Co-author DOI 10.1002/cncr.35936↗
  4. Total Neoadjuvant Therapy for Pancreatic Cancer-What Is Totality? First author DOI 10.1001/jamasurg.2024.0419↗
  5. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations Co-author DOI 10.1016/j.gie.2021.12.001↗
  6. American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review… Co-author DOI 10.1016/j.gie.2021.12.002↗
  7. Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning. Co-author DOI 10.1097/mpa.0000000000002087↗
  8. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  9. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy. First author DOI 10.1001/jamasurg.2019.5090↗
  10. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adeno… Co-author DOI 10.1158/1078-0432.ccr-19-3313↗
  11. Pancreatic Ductal Adenocarcinoma-ESPAC…or It's Back? First author DOI 10.1001/jamasurg.2019.3364↗
  12. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  13. Recent Advances in Pancreatic Cancer Surgery. First author DOI 10.1007/s11938-017-0150-2↗
  14. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/14651858.cd011391.pub2↗
  15. Structured reporting of multiphasic CT for pancreatic cancer: potential effect on staging and surgical planning. Co-author DOI 10.1148/radiol.14140206↗
  16. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  17. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). First author DOI 10.1016/j.surg.2014.02.009↗
  18. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗
  19. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand? First author DOI 10.1097/smj.0000000000000088↗
  20. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. Last author DOI 10.1111/j.1477-2574.2012.00571.x↗
  21. Conditional survival in pancreatic cancer: better than expected. Co-author DOI 10.1111/j.1477-2574.2011.00379.x↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Samuele Cannas · 2 shared papers, 2024–2026 · strength 0.66
  2. Mark H. O’Hara · 4 shared papers, 2018–2026 · strength 0.56
  3. Erica L. Carpenter · 3 shared papers, 2020–2026 · strength 0.50
  4. Brian Matthew Wolpin · 3 shared papers, 2021–2026 · strength 0.47
  5. Maxwell T. Trudeau · 2 shared papers, 2019–2020 · strength 0.44
  6. Andrew H. Ko · 3 shared papers, 2021–2026 · strength 0.42
  7. Jacob Edward Till · 2 shared papers, 2020–2026 · strength 0.29
  8. Timothy R. Donahue · 2 shared papers, 2021–2026 · strength 0.27
  9. Brian G. Czito · 2 shared papers, 2021–2026 · strength 0.27
  10. Marsha Reyngold · 2 shared papers, 2021–2026 · strength 0.27
  11. Patricio Marcelo Polanco · 2 shared papers, 2021–2026 · strength 0.27
  12. John W. Kunstman · 2 shared papers, 2021–2026 · strength 0.27
  13. Noelle K. LoConte · 2 shared papers, 2021–2026 · strength 0.27
  14. Robert A. Wolff · 2 shared papers, 2021–2026 · strength 0.27
  15. Courtney L. Scaife · 2 shared papers, 2021–2026 · strength 0.27
  16. Eric K. Nakakura · 2 shared papers, 2021–2026 · strength 0.27
  17. Mokenge Peter Malafa · 2 shared papers, 2021–2026 · strength 0.27
  18. Jeffrey M. Hardacre · 2 shared papers, 2021–2026 · strength 0.27
  19. Dana Backlund Cardin · 2 shared papers, 2021–2026 · strength 0.27
  20. Mary E. Dillhoff · 2 shared papers, 2021–2026 · strength 0.27
  21. Andrew M. Lowy · 2 shared papers, 2021–2026 · strength 0.27
  22. Vincent M. Chung · 2 shared papers, 2021–2026 · strength 0.27
  23. Christos K Fountzilas · 2 shared papers, 2021–2026 · strength 0.27
  24. Amol Kumar Narang · 2 shared papers, 2021–2026 · strength 0.27
  25. Al B. Benson · 2 shared papers, 2021–2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.